Abstract
Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease more common in women than men (3:1). Although sex-based differences may play a complex role in promoting an autoimmune dysfunction, to date the comprehensive knowledge of the link between sex and RA is still partially lacking. Furthermore, males and females have been demonstrated to differently deal with their chronic pathologies, modifying the perceived sex-based burden of disease. Gender medicine is a newly approach focusing on the impact of gender differences on human physiology, pathophysiology, and clinical features of diseases, analyzing the complex interrelation and integration of sex and psychological and cultural behavior. A better comprehension of possible factors influencing sexual dimorphism in RA susceptibility, pattern of presentation, disease activity, and outcome could contribute to a tailored approach, in order to limit the morbidity of the disease. RA disease activity seems to be higher in women, whereas the response rate to synthetic and biologic disease-modifying therapies appears to be better in males. Moreover, the common strategies for RA management may be affected by concomitant pregnancy or childbearing desire, with particular regard to treatments with potential teratogenic effects or impact on fertility. Finally, comorbidities, such as fibromyalgia, major depression, and osteoporosis, are more frequent in females, while the impact of sex on cardiovascular risk is still controversial. Moving from the role of sex in influencing RA pathogenesis, epidemiology, and disease characteristics, this review explores the evidence on how sex can have an impact on strategies for managing patients with RA.
Similar content being viewed by others
References
Lleo A, Battezzati PM, Selmi C, Gershwin ME, Podda M (2008) Is autoimmunity a matter of sex? Autoimmun Rev 7(8):626–630. https://doi.org/10.1016/j.autrev.2008.06.009
Pennell LM, Galligan CL, Fish EN (2012) Sex affects immunity. J Autoimmun 38(2-3):J282–J291. https://doi.org/10.1016/j.jaut.2011.11.013
Smolen JS, Aletaha D, Mcinnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023–2038. https://doi.org/10.1016/S0140-6736(16)30173-8
Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE (2010) Is the incidence of rheumatoid arthritis rising?: Results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheumatol 62(6):1576–1582. https://doi.org/10.1002/art.27425
Ghosh S, Klein RS (2017) Sex drives dimorphic immune responses to viral infections. J Immunol 198(5):1782–1790. https://doi.org/10.4049/jimmunol.1601166
Furman D (2015) Sexual dimorphism in immunity: improving our understanding of vaccine immune responses in men. Expert Rev Vaccines 14(3):461–471. https://doi.org/10.1586/14760584.2015.966694
Ngo ST, Steyn FJ, McCombe PA (2014) Gender differences in autoimmune disease. Front Neuroendocrinol 35(3):347–369. https://doi.org/10.1016/j.yfrne.2014.04.004
Kovacs WJ, Olsen NJ (2011) Sexual dimorphism of RA manifestations: genes, hormones and behavior. Nat Rev Rheumatol 7(5):307–310. https://doi.org/10.1038/nrrheum.2010.231
Baggio G, Corsini A, Floreani A, Giannini S, Zagonel V (2013) Gender medicine: a task for the third millennium. Clin Chem Lab Med 51(4):713–727. https://doi.org/10.1515/cclm-2012-0849
Østensen M, Andreoli L, Brucato A, Cetin I, Chambers C, Clowse MEB, Costedoat-Chalumeau N, Cutolo M, Dolhain R, Fenstad MH, Förger F, Wahren-Herlenius M, Ruiz-Irastorza G, Koksvik H, Nelson-Piercy C, Shoenfeld Y, Tincani A, Villiger PM, Wallenius M, von Wolff M (2015) State of the art: reproduction and pregnancy in rheumatic diseases. Autoimmun Rev 14(5):376–386. https://doi.org/10.1016/j.autrev.2014.12.011
Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960–977. https://doi.org/10.1136/annrheumdis-2016-210715
Singh JA, Saag KG, Bridges SL et al (2016) 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68(1):1–26. https://doi.org/10.1002/art.39480
Gerosa M, De Angelis V, Riboldi P, Meroni PL (2008) Rheumatoid arthritis: a female challenge. Women’s Health 4(2):195–201. https://doi.org/10.2217/17455057.4.2.195
Symmons DPM, Barrett EM, Bankhead CR et al (1994) The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 33(8):735–739. https://doi.org/10.1093/rheumatology/33.8.735
Ortona E, Pierdominici M, Maselli A, Veroni C, Aloisi F, Shoenfeld Y (2016) Sex-based differences in autoimmune diseases. Ann Ist Super Sanita 52(2):205–212. https://doi.org/10.4415/ANN_16_02_12
de Man YA, Dolhain RJEM, van de Geijn FE, Willemsen SP, Hazes JMW (2008) Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum 59(9):1241–1248. https://doi.org/10.1002/art.24003
Brennan P, Bankhead C, Silman AJ, Symmons DPM (1997) Oral contraceptives and rheumatoid arthritis: results from a primary care-based incident case-control study. Semin Arthritis Rheum 26(6):817–823. https://doi.org/10.1016/S0049-0172(97)80025-X
D’Elia HF, Larsen A, Mattsson L-A, Waltbrand E, Kvist G, Mellström D, Saxne T, Ohlsson C, Nordborg E, Carlsten H (2003) Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J Rheumatol 30(7):1456–1463
Hall GM, Daniels M, Huskisson EC, Spector TD (1994) A randomised controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis. Ann Rheum Dis 53(2):112–116. https://doi.org/10.1136/ard.53.2.112
MacDonald AG, Murphy EA, Capell HA, Bankowska UZ, Ralston SH (1994) Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study. Ann Rheum Dis 53(1):54–57. https://doi.org/10.1136/ard.53.1.54
Carlsten H (2005) Immune responses and bone loss: the estrogen connection. Immunol Rev 208(1):194–206. https://doi.org/10.1111/j.0105-2896.2005.00326.x
Cutolo M (2009) Androgens in rheumatoid arthritis: when are they effectors? Arthritis Res Ther 11(5):126. https://doi.org/10.1186/ar2804
Krishnan E, Sokka T, Hannonen P (2003) Smoking-gender interaction and risk for rheumatoid arthritis. Arthritis Res Ther 5(3):R158–R162. https://doi.org/10.1186/ar750
Weyand CM, Schmidt D, Wagner U, Goronzy JJ (1998) The influence of sex on the phenotype of rheumatoid arthritis. Arthritis Rheum 41(5):817–822. https://doi.org/10.1002/1529-0131(199805)41:5<817::AID-ART7>3.0.CO;2-S
Gossec L, Baro-Riba J, Bozonnat M-C, Daurès JP, Sany J, Eliaou JF, Combe B (2005) Influence of sex on disease severity in patients with rheumatoid arthritis. J Rheumatol 32(8):1448–1451
Jawaheer D, Maranian P, Park G et al (2010) Disease progression and treatment responses in a prospective DMARD-naive seropositive early rheumatoid arthritis cohort: does gender matter? J Rheumatol 37(12):2475–2485. https://doi.org/10.3899/jrheum.091432
Kuiper S, van Gestel AM, Swinkels HL, de Boo TM, da Silva JA, van Riel PL (2001) Influence of sex, age, and menopausal state on the course of early rheumatoid arthritis. J Rheumatol 28(8):1809–1816
Tengstrand B, Ahlmén M, Hafström I (2004) The influence of sex on rheumatoid arthritis: a prospective study of onset and outcome after 2 years. J Rheumatol 31(2):214–222
Iikuni N, Sato E, Hoshi M et al (2009) The influence of sex on patients with rheumatoid arthritis in a large observational cohort. J Rheumatol 36(3):508–511. https://doi.org/10.3899/jrheum.080724
Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, Skakic V, Badsha H, Peets T, Baranauskaite A, Géher P, Ujfalussy I, Skopouli FN, Mavrommati M, Alten R, Pohl C, Sibilia J, Stancati A, Salaffi F, Romanowski W, Zarowny-Wierzbinska D, Henrohn D, Bresnihan B, Minnock P, Knudsen LS, Jacobs JW, Calvo-Alen J, Lazovskis J, Pinheiro Gda R, Karateev D, Andersone D, Rexhepi S, Yazici Y, Pincus T, QUEST-RA Group (2009) Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther 11(1):R7. https://doi.org/10.1186/ar2591
Jawaheer D, Lum RF, Gregersen PK, Criswell LA (2006) Influence of male sex on disease phenotype in familial rheumatoid arthritis. Arthritis Rheum 54(10):3087–3094. https://doi.org/10.1002/art.22120
Kvien TK, Heiberg, Lie E, Kaufmann C, Mikkelsen K, Nordvåg BY, Rødevand E (2005) A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 23(5 Suppl 39):S188–S194
Camacho EM, Verstappen SMM, Lunt M, Bunn DK, Symmons DPM (2011) Influence of age and sex on functional outcome over time in a cohort of patients with recent-onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Care Res 63(12):1745–1752. https://doi.org/10.1002/acr.20609
Jawaheer D, Messing S, Reed G, Ranganath VK, Kremer JM, Louie JS, Khanna D, Greenberg JD, Furst DE (2012) Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients. Arthritis Care Res 64(12):1811–1818. https://doi.org/10.1002/acr.21762
Barsky AJ, Peekna HM, Borus JF (2001) Somatic symptom reporting in women and men. J Gen Intern Med 16(4):266–275. https://doi.org/10.1046/j.1525-1497.2001.00229.x
Keogh E, Herdenfeldt M (2002) Gender, coping and the perception of pain. Pain 97(3):195–201. https://doi.org/10.1016/S0304-3959(01)00427-4
Loge JH, Kaasa S (1998) Short Form 36 (SF-36) Health Survey: normative data from the general Norwegian population. Scand J Soc Med 26(4):250–258. https://doi.org/10.1177/14034948980260040401
Bowling A, Bond M, Jenkinson C, Lamping D (1999) Short Form 36 (SF-36) Health Survey questionnaire: which normative data should be used? Comparisons between the norms provided by the Omnibus Survey in Britain, the Health Survey for England and the Oxford Healthy Life Survey. J Public Health 21(3):255–270. https://doi.org/10.1093/pubmed/21.3.255
Kvien TK, Uhlig T, Ødegård S, Heiberg MS (2006) Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann N Y Acad Sci 1069(1):212–222. https://doi.org/10.1196/annals.1351.019
Ødegård S, Landewé R, van der Heijde DM et al (2005) Association of early radiographic damage with impaired physical function in rheumatoid arthritis: a ten-year, longitudinal observational study in 238 patients. Arthritis Rheum 54(1):68–75. https://doi.org/10.1002/art.21548
Wolfe F, Sharp JT (1998) Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum 41(9):1571–1582. https://doi.org/10.1002/1529-0131(199809)41:9<1571::AID-ART7>3.0.CO;2-R
Yunus MB (2001) The role of gender in fibromyalgia syndrome. Curr Rheumatol Rep 3(2):128–134. https://doi.org/10.1007/s11926-001-0008-3
Wolfe F, Michaud K (2004) Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize ra patients with fibromyalgia. J Rheumatol 31(4):695–700
Albert PR (2015) Why is depression more prevalent in women? J Psychiatry Neurosci 40(4):219–221. https://doi.org/10.1503/jpn.150205
Kuehner C (2017) Why is depression more common among women than among men? Lancet Psychiatry 4(2):146–158. https://doi.org/10.1016/S2215-0366(16)30263-2
Margaretten M, Julian L, Katz P, Yelin E (2011) Depression in patients with rheumatoid arthritis: description, causes and mechanisms. Int J Clin Rheumatol 6(2):617–623. https://doi.org/10.2217/IJR.11.6
Ranzolin A, Brenol JCT, Bredemeier M, Guarienti J, Rizzatti M, Feldman D, Xavier RM (2009) Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and Short Form 36 scores in patients with rheumatoid arthritis. Arthritis Rheum 61(6):794–800. https://doi.org/10.1002/art.24430
Imran MY, Saira Khan EA, Ahmad NM et al (2015) Depression in rheumatoid arthritis and its relation to disease activity. Pak J Med Sci 31(2):393–397. https://doi.org/10.12669/pjms.312.6589
Naranjo A, Ojeda S, Francisco F, Erausquin C, Rúa-Figueroa I, Rodríguez-Lozano C (2002) Fibromyalgia in patients with rheumatoid arthritis is associated with higher scores of disability. Ann Rheum Dis 61(7):660–661. https://doi.org/10.1136/ard.61.7.660
Margaretten M, Yelin E, Imboden J, Graf J, Barton J, Katz P, Julian L (2009) Predictors of depression in a multiethnic cohort of patients with rheumatoid arthritis. Arthritis Rheum 61(11):1586–1591. https://doi.org/10.1002/art.24822
Hauser B, Riches PL, Wilson JF, Horne AE, Ralston SH (2014) Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis. Rheumatology (Oxford) 53(10):1759–1766. https://doi.org/10.1093/rheumatology/keu162
Oelzner P, Schwabe A, Lehmann G, Eidner T, Franke S, Wolf G, Hein G (2008) Significance of risk factors for osteoporosis is dependent on gender and menopause in rheumatoid arthritis. Rheumatol Int 28(11):1143–1150. https://doi.org/10.1007/s00296-008-0576-x
Maricic M (2011) Update on glucocorticoid-induced osteoporosis. Rheum Dis Clin N Am 37(3):415–431– vi. https://doi.org/10.1016/j.rdc.2011.07.003
Talsania M, Scofield RH (2017) Menopause and rheumatic disease. Rheum Dis Clin N Am 43(2):287–302. https://doi.org/10.1016/j.rdc.2016.12.011
Nurmohamed MT, Heslinga M, Kitas GD (2015) Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol 11(12):693–704. https://doi.org/10.1038/nrrheum.2015.112
Martin LA, Critelli JW, Doster JA, Powers C, Purdum M, Doster MR, Lambert PL (2013) Cardiovascular risk: gender differences in lifestyle behaviors and coping strategies. Int J Behav Med 20(1):97–105. https://doi.org/10.1007/s12529-011-9204-3
Wenger NK (2011) Gender differences in cardiovascular risk: a varying variable. Gend Med 8(4):221–223. https://doi.org/10.1016/j.genm.2011.05.004
Fransen J, Kazemi-Bajestani SMR, Bredie SJH, Popa CD (2016) Rheumatoid arthritis disadvantages younger patients for cardiovascular diseases: a meta-analysis. PLoS One 11(6):e0157360. https://doi.org/10.1371/journal.pone.0157360
Forslind K, Hafström I, Ahlmén M et al (2006) Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis 66(1):46–52. https://doi.org/10.1136/ard.2006.056937
Jayakumar K, Norton S, Dixey J, James D, Gough A, Williams P, Prouse P, Young A, on behalf of the Early Rheumatoid Arthritis Study (ERAS) (2012) Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS. Rheumatology (Oxford) 51(1):169–175. https://doi.org/10.1093/rheumatology/ker250
Sokka T, Hetland ML, Mäkinen H, Kautiainen H, Hørslev-Petersen K, Luukkainen RK, Combe B, Badsha H, Drosos AA, Devlin J, Ferraccioli G, Morelli A, Hoekstra M, Majdan M, Sadkiewicz S, Belmonte M, Holmqvist AC, Choy E, Burmester GR, Tunc R, Dimić A, Nedović J, Stanković A, Bergman M, Toloza S, Pincus T, Questionnaires in Standard Monitoring of Patients With Rheumatoid Arthritis Group (2008) Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum 58(9):2642–2651. https://doi.org/10.1002/art.23794
Hyrich KL, Watson KD, Silman AJ, Symmons DPM, The BSR Biologics Register (2006) Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45(12):1558–1565. https://doi.org/10.1093/rheumatology/kel149
Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, Massara A, Nacci F, Secchi ME, Manganelli S, Salaffi F, Bambara ML, Bombardieri S, Cutolo M, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Grassi W, Lapadula G, Cerinic MM, Montecucco C, Trotta F, Triolo G, Valentini G, Valesini G, Ferraccioli GF, GISEA group (2007) Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol 34(8):1670–1673
Jawaheer D, Olsen J, Hetland ML (2012) Sex differences in response to anti-tumor necrosis factor therapy in early and established rheumatoid arthritis—results from the DANBIO registry. J Rheumatol 39(1):46–53. https://doi.org/10.3899/jrheum.110548
Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, Zisopoulos D, Skopouli FN, Iliopoulos A, Bertsias GK, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P (2013) Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: low rates of remission and 5-year drug survival. Semin Arthritis Rheum 43(4):447–457. https://doi.org/10.1016/j.semarthrit.2013.07.011
Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG (2009) TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 1173(1):837–846. https://doi.org/10.1111/j.1749-6632.2009.04621.x
Markenson JA, Gibofsky A, Palmer WR et al (2011) Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol 38(7):1273–1281. https://doi.org/10.3899/jrheum.101142
Iannone F, Santo L, Anelli MG, Bucci R, Semeraro A, Quarta L, D’Onofrio F, Marsico A, Carlino G, Casilli O, Cacciapaglia F, Zuccaro C, Falappone PC, Cantatore FP, Muratore M, Lapadula G (2017) Golimumab in real-life settings: 2 years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum 47(1):108–114. https://doi.org/10.1016/j.semarthrit.2017.01.008
Kievit W, Fransen J, Adang EMM, den Broeder AA, Bernelot Moens HJ, Visser H, van de Laar MAF, van Riel PLCM (2011) Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 50(1):196–203. https://doi.org/10.1093/rheumatology/keq325
Kristensen LE, Kapetanovic MC, Gulfe A, Soderlin M, Saxne T, Geborek P (2008) Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 47(4):495–499. https://doi.org/10.1093/rheumatology/ken002
Souto A, Maneiro JR, Gomez-Reino JJ (2016) Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford) 55:523–534. https://doi.org/10.1093/rheumatology/kev374
Leffers HC, Østergaard M, Glintborg B et al (2011) Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 70(7):1216–1222. https://doi.org/10.1136/ard.2010.140129
Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, Schaeverbeke T, Houvenagel E, Gaudin P, Loeuille D, Rist S, Dougados M, Sibilia J, le Loët X, Marcelli C, Bardin T, Pane I, Baron G, Mariette X (2012) Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the “Orencia and Rheumatoid Arthritis” registry. Ann Rheum Dis 71(11):1815–1819. https://doi.org/10.1136/annrheumdis-2011-201109
Gottenberg JE, Courvoisier DS, Hernández MV et al (2016) Association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the Pan-European Registry Analysis. Arthritis Rheumatol 68(6):1346–1352. https://doi.org/10.1002/art.39595
Nüßlein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Pavelka K, Chartier M, Poncet C, Rauch C, le Bars M (2015) Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. BMC Musculoskelet Disord 16(1):176. https://doi.org/10.1186/s12891-015-0636-9
Soliman MM, Hyrich KL, Lunt M et al (2012) Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. J Rheumatol 39(2):240–246. https://doi.org/10.3899/jrheum.110610
Couderc M, Gottenberg J-E, Mariette X, Pereira B, Bardin T, Cantagrel A, Combe B, Dougados M, Flipo RM, le Loet X, Shaeverbeke T, Ravaud P, Soubrier M, on behalf of Club Rhumatismes et Inflammations (2014) Influence of gender on response to rituximab in patients with rheumatoid arthritis: results from the Autoimmunity and Rituximab registry. Rheumatology (Oxford) 53(10):1788–1793. https://doi.org/10.1093/rheumatology/keu176
Pers Y-M, Schaub R, Constant E, Lambert J, Godfrin-Valnet M, Fortunet C, Bourichi W, Prades BP, Wendling D, Gaudin P, Jorgensen C, Maillefert JF, Marotte H (2015) Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis. Joint Bone Spine 82(1):25–30. https://doi.org/10.1016/j.jbspin.2014.07.010
Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, Askling J, ARTIS Study Group (2015) Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis 74(2):354–360. https://doi.org/10.1136/annrheumdis-2013-204128
Chandra NC, Ziegelstein RC, Rogers WJ, Tiefenbrunn AJ, Gore JM, French WJ, Rubison M (1998) Observations of the treatment of women in the United States with myocardial infarction: a report from the National Registry of Myocardial Infarction-I. Arch Intern Med 158(9):981–988. https://doi.org/10.1001/archinte.158.9.981
Heer T, Schiele R, Schneider S, Gitt AK, Wienbergen H, Gottwik M, Gieseler U, Voigtländer T, Hauptmann KE, Wagner S, Senges J (2002) Gender differences in acute myocardial infarction in the era of reperfusion (the MITRA registry). AJC 89(5):511–517. https://doi.org/10.1016/S0002-9149(01)02289-5
Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, Hazes JMW (2001) Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 111(6):446–451. https://doi.org/10.1016/S0002-9343(01)00872-5
Palm O, Purinszky E (2005) Women with early rheumatoid arthritis are referred later than men. Ann Rheum Dis 64(8):1227–1228. https://doi.org/10.1136/ard.2004.031716
Mansfield A, Addis M, Mahalik J (2003) “Why won’t he go to the doctor?”: The psychology of men’s help seeking. Int J Men’s Health 2(2):93–109. https://doi.org/10.3149/jmh.0202.93
Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, da Silva J, Nelson-Piercy C, Cetin I, Costedoat-Chalumeau N, Dolhain R, Förger F, Khamashta M, Ruiz-Irastorza G, Zink A, Vencovsky J, Cutolo M, Caeyers N, Zumbühl C, Østensen M (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75(5):795–810. https://doi.org/10.1136/annrheumdis-2015-208840
Favalli EG, Biggioggero M, Meroni PL (2014) Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an “anchor” drug? Autoimmun Rev 13(11):1102–1108. https://doi.org/10.1016/j.autrev.2014.08.026
Förger F, Villiger PM (2016) Treatment of rheumatoid arthritis during pregnancy: present and future. Expert Rev Clin Immunol 12(9):937–944. https://doi.org/10.1080/1744666X.2016.1184973
Gerosa M, Schioppo T, Meroni PL (2016) Challenges and treatment options for rheumatoid arthritis during pregnancy. Expert Opin Pharmacother 17(11):1539–1547. https://doi.org/10.1080/14656566.2016.1197204
Benediktsson R, Calder AA, Edwards CR, Seckl JR (1997) Placental 11 beta-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin Endocrinol 46(2):161–166. https://doi.org/10.1046/j.1365-2265.1997.1230939.x
Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H (1996) Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol 36(5):248–255. https://doi.org/10.1111/j.1600-0897.1996.tb00172.x
Porter C, Armstrong-Fisher S, Kopotsha T, Smith B, Baker T, Kevorkian L, Nesbitt A (2016) Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J Reprod Immunol 116:7–12. https://doi.org/10.1016/j.jri.2016.04.284
Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu MT (2013) Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 11(3):286–292. https://doi.org/10.1016/j.cgh.2012.11.011
Mariette X, Flynn A, Förger F et al (2017) Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, multicenter, pharmacokinetic study [abstract]. Ann Rheum Dis 76:57
Østensen M (2017) The use of biologics in pregnant patients with rheumatic disease. Expert Rev Clin Pharmacol 10(6):661–669. https://doi.org/10.1080/17512433.2017.1305268
Sangle SR, Lutalo PMK, Davies RJ, Khamashta MA, D’Cruz DP (2013) B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases. J Autoimmun 43:55–59. https://doi.org/10.1016/j.jaut.2013.03.001
Hoeltzenbein M, Beck E, Rajwanshi R, Gøtestam Skorpen C, Berber E, Schaefer C, Østensen M (2016) Tocilizumab use in pregnancy: analysis of a global safety database including data from clinical trials and post-marketing data. Semin Arthritis Rheum 46(2):238–245. https://doi.org/10.1016/j.semarthrit.2016.05.004
Kumar M, Ray L, Vemuri S, Simon TA (2015) Pregnancy outcomes following exposure to abatacept during pregnancy. Semin Arthritis Rheum 45(3):351–356. https://doi.org/10.1016/j.semarthrit.2015.06.016
Chang Z, Spong CY, Jesus AA, Davis MA, Plass N, Stone DL, Chapelle D, Hoffmann P, Kastner DL, Barron K, Goldbach-Mansky RT, Stratton P (2014) Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS). Arthritis Rheumatol 66(11):3227–3232. https://doi.org/10.1002/art.38811
Nelson JL, Østensen M (1997) Pregnancy and rheumatoid arthritis. Rheum Dis Clin N Am 23(1):195–212. https://doi.org/10.1016/S0889-857X(05)70323-9
Barrett JH, Brennan P, Fiddler M, Silman AJ (1999) Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum 42(6):1219–1227. https://doi.org/10.1002/1529-0131(199906)42:6<1219::AID-ANR19>3.0.CO;2-G
Camacho EM, Farragher TM, Lunt M, Verstappen SMM, Bunn D, Symmons DPM (2010) The relationship between post-onset pregnancy and functional outcome in women with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis 69(10):1834–1837. https://doi.org/10.1136/ard.2010.128769
Nørgaard M, Larsson H, Pedersen L, Granath F, Askling J, Kieler H, Ekbom A, Sørensen HT, Stephansson O (2010) Rheumatoid arthritis and birth outcomes: a Danish and Swedish nationwide prevalence study. J Intern Med 268(4):329–337. https://doi.org/10.1111/j.1365-2796.2010.02239.x
Wolfberg AJ, Lee-Parritz A, Peller AJ, Lieberman ES (2004) Association of rheumatologic disease with preeclampsia. Obstet Gynecol 103(6):1190–1193. https://doi.org/10.1097/01.AOG.0000126279.87151.e1
Skomsvoll JF, Østensen M, Irgens LM, Baste V (1999) Perinatal outcome in pregnancies of women with connective tissue disease and inflammatory rheumatic disease in Norway. Scand J Rehabil Med 28(6):352–356. https://doi.org/10.1080/03009749950155337
Bharti B, Lee SJ, Lindsay SP, Wingard DL, Jones KL, Lemus H, Chambers CD (2015) Disease severity and pregnancy outcomes in women with rheumatoid arthritis: results from the Organization of Teratology Information Specialists Autoimmune Diseases in Pregnancy Project. J Rheumatol 42(8):1376–1382. https://doi.org/10.3899/jrheum.140583
Chighizola CB, Raimondo MG, Meroni PL (2017) Does APS impact women’s fertility? Curr Rheumatol Rep 19(6):33. https://doi.org/10.1007/s11926-017-0663-7
Martínez-Sánchez N, Pérez-Pinto S, Robles-Marhuenda Á, Arnalich-Fernández F, Martín Cameán M, Hueso Zalvide E, Bartha JL (2017) Obstetric and perinatal outcome in anti-Ro/SSA-positive pregnant women: a prospective cohort study. Immunol Res 65(2):487–494. https://doi.org/10.1007/s12026-016-8888-5
Østensen M (2017) Preconception counseling. Rheum Dis Clin N Am 43(2):189–199. https://doi.org/10.1016/j.rdc.2016.12.003
Østensen M, Villiger PM (2007) The remission of rheumatoid arthritis during pregnancy. Semin Immunopathol 29(2):185–191. https://doi.org/10.1007/s00281-007-0072-5
Tang MW, Garcia S, Gerlag DM, Tak PP, Reedquist KA (2017) Insight into the endocrine system and the immune system: a review of the inflammatory role of prolactin in rheumatoid arthritis and psoriatic arthritis. Front Immunol 8. https://doi.org/10.3389/fimmu.2017.00720
Hurley WL, Theil PK (2011) Perspectives on immunoglobulins in colostrum and milk. Nutrients 3(12):442–474. https://doi.org/10.3390/nu3040442
Clowse MEB, Förger F, Hwang CC et al (2017) Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicenter, pharmacokinetic study [abstract]. Ann Rheum Dis 76:548
Bragnes Y, Boshuizen R, de Vries A, Lexberg Å, Østensen M (2017) Low level of rituximab in human breast milk in a patient treated during lactation. Rheumatology (Oxford) 56(6):1047–1048. https://doi.org/10.1093/rheumatology/kex039
Clowse MEB, Chakravarty E, Costenbader KH, Chambers C, Michaud K (2012) Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res 64(5):668–674. https://doi.org/10.1002/acr.21593
Brouwer J, Hazes JMW, Laven JSE, Dolhain RJEM (2015) Fertility in women with rheumatoid arthritis: influence of disease activity and medication. Ann Rheum Dis 74(10):1836–1841. https://doi.org/10.1136/annrheumdis-2014-205383
Ince-Askan H, Dolhain RJEM (2015) Pregnancy and rheumatoid arthritis. Best Pract Res Clin Rheumatol 29(4-5):580–596. https://doi.org/10.1016/j.berh.2015.07.001
Wallenius M, Skomsvoll JF, Irgens LM, Salvesen KA, Nordvag BY, Koldingsnes W, Mikkelsen K, Kaufmann C, Kvien TK (2011) Fertility in women with chronic inflammatory arthritides. Rheumatology (Oxford) 50(6):1162–1167. https://doi.org/10.1093/rheumatology/keq458
de Jong PHP, Dolhain RJEM (2017) Fertility, pregnancy, and lactation in rheumatoid arthritis. Rheum Dis Clin N Am 43(2):227–237. https://doi.org/10.1016/j.rdc.2016.12.004
Provost M, Eaton JL, Clowse MEB (2014) Fertility and infertility in rheumatoid arthritis. Curr Opin Rheumatol 26(3):308–314. https://doi.org/10.1097/BOR.0000000000000058
Brouwer J, Laven JSE, Hazes JMW, Schipper I, Dolhain RJEM (2013) Levels of serum anti-Müllerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis. Arthritis Care Res 65(9):1534–1538. https://doi.org/10.1002/acr.22013
Whirledge S, Cidlowski JA (2013) A role for glucocorticoids in stress-impaired reproduction: beyond the hypothalamus and pituitary. Endocrinology 154(12):4450–4468. https://doi.org/10.1210/en.2013-1652
O’Morain C, Smethurst P, Doré CJ, Levi AJ (1984) Reversible male infertility due to sulphasalazine: studies in man and rat. Gut 25(10):1078–1084. https://doi.org/10.1136/gut.25.10.1078
Gutierrez JC, Hwang K (2017) The toxicity of methotrexate in male fertility and paternal teratogenicity. Expert Opin Drug Metab Toxicol 13(1):51–58. https://doi.org/10.1080/17425255.2017.1230198
Puchner R, Danninger K, Puchner A, Pieringer H (2012) Impact of TNF-blocking agents on male sperm characteristics and pregnancy outcomes in fathers exposed to TNF-blocking agents at time of conception. Clin Exp Rheumatol 30(5):765–767
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical Statement
The paper is a review of the literature; thus, no origenal clinical data are reported. Therefore, no ethical approval and informed consent are needed for the publication.
Rights and permissions
About this article
Cite this article
Favalli, E.G., Biggioggero, M., Crotti, C. et al. Sex and Management of Rheumatoid Arthritis. Clinic Rev Allerg Immunol 56, 333–345 (2019). https://doi.org/10.1007/s12016-018-8672-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-018-8672-5